Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
862 studies found for:    Open Studies | "Prostatic Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms
Condition: Prostatic Neoplasms
Interventions: Procedure: Irreversible electroporation (IRE);   Device: NanoKnife
2 Recruiting A Registry of Participants With Prostate Cancer in Asia
Condition: Prostatic Neoplasms
Intervention: Other: No Intervention
3 Recruiting Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Enzalutamide;   Drug: Conventional NSAA;   Drug: LHRHA;   Radiation: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
4 Recruiting Collection of Blood From Patients With Prostate Cancer
Condition: Prostatic Neoplasms
Intervention:
5 Recruiting Gallium-68 Citrate PET Used in Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Procedure: Gallium-68 citrate PET
6 Not yet recruiting Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Radiation: Stereotactic body RT with MR-guided boost
7 Recruiting Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Enzalutamide;   Drug: NSAA;   Drug: LHRHA or Surgical Castration
8 Recruiting Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Doxorubicin;   Drug: Ketoconazole;   Drug: Docetaxel;   Drug: Estramustine;   Drug: Degarelix
9 Not yet recruiting Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
Condition: Prostatic Neoplasm
Intervention: Drug: Perflutren Lipid Microsphere Intravenous Suspension
10 Recruiting Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Procedure: Prostatectomy/Surgery;   Other: Radiotherapy with adjuvant androgen deprivation therapy
11 Recruiting A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Apalutamide;   Drug: Placebo
12 Recruiting Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)
13 Not yet recruiting ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: BAY 1841788 / ODM-201;   Drug: Standard ADT (androgen deprivation therapy);   Drug: Docetaxel;   Drug: Placebo
14 Not yet recruiting Single Fraction HDR Brachytherapy Plus Hypofractionated EBRT for Low-risk Prostate Cancer: Phase II Trial
Condition: Prostatic Neoplasms
Intervention: Radiation: HDR brachytherapy + hypofractionated EBRT
15 Recruiting A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Interventions: Drug: JNJ 56021927;   Drug: Drug Cocktail;   Drug: Pioglitazone;   Drug: Rosuvastatin
16 Recruiting First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Biological: BAY2010112
17 Recruiting An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Condition: Prostatic Neoplasms
Interventions: Drug: JNJ-56021927;   Drug: Bicalutamide;   Drug: Bicalutamide Placebo;   Drug: JNJ-56021927 Placebo;   Drug: GnRH (agonist);   Radiation: 74-80 Grays (units of radiation)
18 Recruiting Institut Paoli Calmettes Prostate Cancer Database
Condition: Prostatic Neoplasms
Intervention: Other: Data collection
19 Recruiting Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Condition: Prostatic Neoplasms
Interventions: Biological: Pembrolizumab 200 mg;   Drug: Olaparib 400 mg;   Drug: Docetaxel 75 mg/m^2;   Drug: Prednisone 5 mg;   Drug: Enzalutamide 160 mg;   Other: Dexamethasone 8 mg
20 Recruiting Stereotactic Radiotherapy for Oligometastatic Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Radiation: stereotactic radiotherapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.